61 results about "Meglumine" patented technology

The invention relates to the technical field of medicines, in particular to a compound amlodipine atorvastatin calcium tablet and a production mixing device. The compound amlodipine atorvastatin calcium tablet is a core-coated tablet and comprises an inner-layer tablet core containing atorvastatin calcium and an outer-layer tablet layer containing amlodipine besylate, the inner-layer tablet core further comprises meglumine and sodium lauryl sulfate, the mass ratio of meglumine to sodium lauryl sulfate is (0.5-5): 1, the mass ratio of meglumine to sodium lauryl sulfate is (0.5-5): 1, and the mass ratio of meglumine to sodium lauryl sulfate is (0.5-5): 1. And the mass of the meglumine accounts for 1-3% of the total mass of the inner-layer tablet core. The amlodipine and atorvastatin calcium are prepared into the coated tablet, so that two active ingredients in the same tablet are effectively isolated, and the compatibility of the atorvastatin calcium and the amlodipine besylate is remarkably improved; meanwhile, the inner layer and the outer layer of the core-coated sheet are separately granulated before tabletting, so that the problem that the mixing uniformity of total mixed particles is relatively poor when conventional tablets are prepared is effectively solved.

The invention discloses a rivaroxaban tablet. A tablet core is prepared from the following components in parts by weight: 10 parts of rivaroxaban, 15-25 parts of meglumine, 50-80 parts of a filling agent, 20-40 parts of a disintegrating agent and 0.5-1.5 parts of a lubricating agent; wherein the particle size D90 of the rivaroxaban is 50-100 [mu] m, and the invention discloses a preparation method of the rivaroxaban tablet, and the meglumine and the rivaroxaban are adopted to form a stable clathrate compound to prepare the preparation, so that the dissolution rate and the stability of the rivaroxaban tablet can be improved.

The invention relates to the field of agricultural bactericides, in particular to a suspending agent containing fenaminstrobin and validamycin A and application of the suspending agent. The bactericidal composition comprises a suspending agent containing fenaminstrobin and validamycin A, an active component, a stabilizer, an auxiliary agent and water, the active component accounts for 1-70% of the mass of the preparation, and the stabilizer accounts for 0.1-10% of the mass of the preparation; wherein the active ingredients are fenaminstrobin and validamycin A, and the stabilizer is meglumine (N-methyl-D-glucosamine). The suspending agent prepared by the technical scheme of the invention effectively inhibits the increase of the particle size of a sample in the thermal storage process of a preparation, effectively improves the suspension rate of fenaminstrobin after the thermal storage of the preparation, improves the utilization rate of a pesticide, and ensures the normal exertion of the efficacy of the pesticide at the same time. Meanwhile, the quality of the active components of the stabilizer-containing bactericide is stable within the shelf life, the addition of the stabilizer does not cause the decomposition of the active components, and the preparation does not have obvious physical or chemical change.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride-containing oral liquid and application thereof, and the ambroxol hydrochloride oral liquid is composed of ambroxol hydrochloride, ligustrazine, meglumine, dextran 40, xylitol, carboxymethylcellulose, L-tryptophan, stevioside and purified water. The ligustrazine and the ambroxol hydrochloride play a synergistic effect, and the meglumine and the dextran 40 are combined for use, so that the stability of the ambroxol hydrochloride is improved. Accelerated experiments show that the ambroxol hydrochloride is stable in property and suitable for further industrial mass production.

The invention relates to the technical field of medicines, and provides a nalmefene hydrochloride injection and a preparation method thereof, every 1000 injections comprise the following components in parts by weight: 2.0 g of nalmefene hydrochloride based on nalmefene, 18g of osmotic pressure regulator, 0.05-0.1 g of meglumine, and the balance of water for injection to 2000mL. The preparation method comprises the following steps: S1, adding the osmotic pressure regulator and the meglumine in a prescription dosage into the water for injection which accounts for 90% of the total amount of the prescription dosage, stirring until the osmotic pressure regulator and the meglumine are dissolved, and regulating the pH value to 3.5-4.0 through a hydrochloric acid solution; s2, adding a prescription amount of nalmefene hydrochloride into the solution in the step S1, stirring until the nalmefene hydrochloride is dissolved, and adjusting the pH value to 3.5-3.8; and S3, adding water for injection to the total amount, uniformly stirring, filtering, canning into an ampoule bottle, sterilizing, carrying out lamp detection for leakage detection, and packaging. By adding a small amount of meglumine, the amount of the dinalmefene impurity generated by long-term placement and oxidation of the nalmefene hydrochloride injection can be reduced, adverse reactions possibly caused by a large amount of meglumine are reduced, the content of the dinalmefene impurity is maintained at a low level, and the use safety of the injection is improved.

This invention relates to an isosorbide dinitrate pharmaceutical composition injection and its preparation method. In addition to isosorbide dinitrate, the injection formulation also contains meglumine and glutathione. The preferred specifications are 5ml:5mg and 10ml:10mg. The isosorbide dinitrate injection prepared according to the formulation and process of this invention has the characteristics of high excipient safety, simple process, extremely high quality stability and good safety, which is significantly better than the prior art.

A composition for carbon dioxide (CO2) capture includes 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, or combinations thereof. A process of CO2 capture includes mixing a CO2-containing gas with the composition. A system includes a component for receiving a gas and the composition, which absorbs CO2 from the gas. A further composition includes a first amine solvent selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine and a second amine solvent independently selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, ethyl diethanolamine, dimethylethanolamine, piperidine, 2-amino-2-methyl-1-propanol, and monoethanolamine. A further process includes reacting CO2 with an amine selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The present invention relates to a method for producing gadoteric acid meglumine using high-purity tetraracetam (DOTA). This method does not require the use of organic solvents and optimizes synthesis process conditions. The synthesis process for producing gadoteric acid meglumine using tetraracetam includes at least one electrodialysis purification step. This step can produce tetraracetam and gadoteric acid meglumine with minimal impurity content.

Salts of R-ketorolac, including solid salts, such as crystalline salts of the meglumine and tromethamine salts R-ketorolac, are disclosed. Methods of preparing such salts, pharmaceutical compositions comprising salts, and methods of treating cancer with such salts are further provided.

The invention provides a crystal form of a compound HIF-117 salt as well as a preparation method and application of the crystal form, and the crystal form is any one or more of the following crystal forms: a hydrochloride crystal form A, a sulfate crystal form B, a 1, 2-ethanedisulfonate crystal form C1, 1, 2-ethanedisulfonate crystal form C2, 1, 2-ethanedisulfonate crystal form C3 and 1, 2-ethanedisulfonate crystal form C4. The crystal form 1, 2-ethanedisulfonate crystal form C2, p-toluenesulfonate crystal form D, mesylate crystal form E1, mesylate crystal form E2, hydrobromide crystal form F1, hydrobromide crystal form F2, sodium salt crystal form G, sylvite crystal form H1, sylvite crystal form H2, calcium salt crystal form I, magnesium salt crystal form J, choline salt crystal form K, lysine salt crystal form L, ammonium salt crystal form M, meglumine salt crystal form N, betaine salt crystal form O1, betaine salt crystal form O2 and diethylamine salt crystal form P1, the invention relates to a diethylamine salt crystal form P1, a diethylamine salt crystal form P2, a diethylamine salt crystal form P3, a diethylamine salt crystal form P4, a diethylamine salt crystal form P5, a tromethamine salt crystal form Q1, a tromethamine salt crystal form Q2 and a tromethamine salt crystal form Q3. The compound has good stability, and has important value for development and production of medicines and preparations.

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm / L.

The utility model relates to the field of medical product processing, in particular to concentration equipment for processing meglumine chlorzolate, which comprises a mounting rack, a concentration tank and a storage tank, the concentration tank is fixed on one side in the mounting rack, a plurality of filtering holes are arranged at the bottom in the concentration tank, and the storage tank is fixed on the other side in the mounting rack. A discharge hopper is arranged at the bottom of the concentration tank corresponding to the outside of the filter-out hole, an electric heating tube with a wiring end extending to the outside is mounted between the bottom in the discharge hopper and the outside of the concentration tank, and the discharge hopper and the bottom of the storage tank are both communicated with a discharge tube. The vacuum pump is used for creating a low-pressure environment, the boiling point of a solvent is reduced, low-temperature evaporation is realized, and the concentration efficiency is greatly improved; through a heating, stirring, condensing and pressure monitoring system which is accurately controlled by an electric heating tube, a motor, a bevel gear and a condenser, the stability of the whole concentration process is ensured, and the quality fluctuation is reduced; safety parts such as a check valve and a pressure gauge can improve safety of the system, and backflow and overpressure risks are prevented.

The present invention relates to new crystal salt forms of sulfasalazine, in particular crystal Form A of the D(-)-N-methylglucamine (meglumine) salt of sulfasalazine (see Figure 1), crystal form A of the piperazine salt of sulfasalazine (see Figure 2) and crystal Form B of the diethylamine salt of sulfasalazine (see Figure 4), which can be obtained by use of the inventive preparation process, a pharmaceutical composition comprising one or more of the inventive crystal salt forms in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and / or the gastro-intestinal tract.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The invention belongs to the technical field of capsule preparations, and relates to a plant starch soft capsule and a preparation method thereof. The plant starch soft capsule is prepared from hydroxypropyl starch, carrageenan, plantain seed gum, sodium alginate, sodium hyaluronate and meglumine. The preparation method comprises the steps of raw material pretreatment, mixing and glue preparation, vacuum degassing, soft capsule forming and drying. Through the innovative raw material ratio and preparation process, the soft capsule has excellent weather resistance and can adapt to transportation and storage at extreme temperature; meanwhile, the product is mainly prepared from plant source raw materials, so that the fishy smell caused by gelatin is eliminated, and the use comfort and the market acceptability are improved. The plant starch soft capsule can be applied to the field of cosmetics and used as a carrier of active ingredients.

The present invention relates to a liquid pharmaceutical composition comprising (i) totally dissolved tretinoin or a pharmaceutically acceptable isomer thereof; (ii) d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS); (iii) a pH-modifying agent selected in the group consisting of meglumine, potassium hydroxide (KOH), sodium hydroxide (NaOH), sodium acetate (anhydrous, trihydrate, and mixtures thereof), potassium acetate (anhydrous, trihydrate, and mixtures thereof), di-potassium hydrogenophosphate, di-sodium hydrogenophosphate, tri-sodium phosphate, tri-potassium phosphate, and mixtures thereof; and (iv) water. The present invention also relates to the medical uses of such a composition.

The application discloses a super-long chain glucose amide nonionic surfactant and a synthesis method thereof. The hydrophobic tail chain of the surfactant is derived from plant-based fatty acids such as oleic acid, erucic acid or nervonic acid, and the hydrophilic head group is derived from glucose derivatives such as meglumine and glycolglucamine. With oleic acid, erucic acid and nervonic acid in rapeseed by-product as hydrophobic tail chain raw material, glucose derivatives meglumine and glycolglucamine as hydrophilic head group raw material, methanol, ethanol, ethylene glycol or propylene glycol (single solvent or binary mixed solvent) as solvent, and DMAP or NaF as catalyst, a kind of bio-based surfactant is obtained. The super-long chain glucose amide nonionic surfactant is prepared by selective amination reaction, the hydroxyl group in the glucose amine molecule does not need to be protected complicatedly, the reaction temperature is close to room temperature, the operation is simple, and the purification process only needs a simple industrial crystallization method, which is suitable for industrial production.

The present disclosure provides meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof. Also disclosed are methods of treatment using the meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof and methods of making salt compounds of CX3CR1 modulators and polymorphs thereof.

A method produces an aqueous liquid preparation for magnetic resonance contrast that contains a complex of a lanthanide and a macrocyclic chelate together with free chelate. A solution of the macrocyclic chelate in water is prepared, lanthanide and meglumine are added, and complex formation proceeds in the presence of meglumine at a pH between 6.5 and 8.0 with lanthanide in molar excess over meglumine and meglumine in molar excess over the chelate. The pH is then reduced to a target value below 5.0 by incremental addition of an acid such as further chelate, optionally followed by addition of a fixed chelate amount. The pH is subsequently raised above 6.5 with meglumine and the solution is diluted to a final volume, providing an industrial-scale single-vessel process that yields a preparation containing a defined low amount of free lanthanide.

The application provides a sustained-release meglumine microtablet, which is composed of a sustained-release layer, a release layer and a coating layer, the sustained-release layer and the release layer form a double release system, and the release speed of the meglumine is effectively controlled by controlling the drug proportion of the sustained-release layer and the release layer, so that the problem of fast drug release caused by small volume and large specific surface area of the microtablet is solved, and the microtablet realizes long-time and sustained and stable drug release. The meglumine sustained-release microtablet provided by the application has a diameter of 1-3 mm and a tablet weight of 20-60 mg, compared with common tablets, the sustained-release microtablet can reduce the drug administration frequency of patients, realizes once-a-day drug administration, improves the compliance of patients, and can meet the drug administration needs of children, the elderly and patients with dysphagia and the like.

The application belongs to the technical field of medicine, and particularly relates to a ketoprofen in-situ co-amorphous composition. The co-amorphous composition is composed of ketoprofen, lysine, arginine and meglumine, and can spontaneously form a homogeneous disordered arrangement when contacting with an aqueous medium (including a dissolution process). Through powder X-ray diffraction, differential scanning calorimetry and Fourier infrared spectroscopy analysis, the three compositions can be co-amorphized in-situ when contacting with a trace amount of aqueous medium or in a dissolution process, so that the solubility and dissolution rate of ketoprofen are significantly improved, and the oral absorption and therapeutic effect of ketoprofen are expected to be enhanced. Meanwhile, the degree of in-situ co-amorphization is closely related to the molar ratio of the composition, the contacting time, the pH and the temperature of the medium. The application mediates the occurrence of in-situ co-amorphization of ketoprofen through prescription composition and design, improves the solubility and dissolution defects of the drug, and provides a new preparation idea.

The present invention relates to the field of medicine, and provides a tecovirimat composition, a preparation method thereof and an application. The composition contains an active ingredient tecovirimat, a complexing agent cyclodextrin, a solubilizer meglumine and a basic additive, and the weight ratio is 1:(15-30):(0.05-0.2):(0.1-0.2). Among them, the combined use of the three auxiliary materials of the complexing agent, the solubilizer and the basic additive can greatly improve the solubility of the active ingredient tecovirimat. Compared with the prior art, the dosage of each auxiliary material in the composition of the present invention can meet the specified limits in relevant regulations, and the risks of allergy, hemolysis and irritation are relatively low, and the safety of the preparation is better. The preparation method of the composition provided by the present invention is simple and easy to implement, the quality of the preparation finished product is more stable, and the application is more convenient. The composition can be used for treating or preventing virus infections and related diseases caused by orthopoxviruses.

The invention belongs to the technical field of organic synthesis, and particularly relates to a synthetic method of meglumine. The method comprises the following steps: 1) dissolving glucose and methylamine in water to prepare a reaction solution; 2) adding a catalyst into the reaction liquid for reaction; and 3) after the reaction is finished, filtering and separating the catalyst, and carrying out post-treatment on the reaction liquid to obtain the meglumine. On the basis of mature reductive amination reaction, a green and environment-friendly water phase system and an efficient heterogeneous catalysis path are selected, high efficiency and high selectivity of product conversion are achieved by means of the structural advantage of the hierarchical porous Ni / SiO2-Hier catalyst and the requirement high matching capacity of a reaction system, and the method has the synthesis advantages of being green and efficient.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a celecoxib tablet and a preparation method thereof.The celecoxib tablet is composed of celecoxib, lactose-microcrystalline cellulose compounded according to a specific proportion, polyvinylpolypyrrolidone-carboxymethyl starch sodium, a lubricant and a solubilizing stabilizer. Wherein the solubilizing stabilizer is beta-cyclodextrin, sodium stearoyl lactylate and meglumine. The preparation method comprises the steps of pretreatment of the celecoxib and the solubilizing stabilizer, step-by-step granulation, drying and size stabilization, and total mixing and tabletting. Through the synergistic effect of the compound solubilizing stabilizer and the wet grinding process and in combination with the preparation method of step-by-step mixing granulation, the content uniformity, the dissolution performance and the storage stability of the prepared celecoxib tablet are remarkably improved, and the preparation process is simple and easy to operate and suitable for industrial large-scale production.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oxaliplatin-containing microcapsule and a preparation method thereof. The microcapsules are prepared from the following components in parts by weight: 50 parts of oxaliplatin, 5 to 10 parts of meglumine, 1 to 5 parts of lacrotitol, 34.5 to 56.8 parts of Arabic gum, 15 to 33 parts of L-proline, 3.5 to 5.5 parts of polyethylene glycol 6000 and 4 to 8 parts of polyvinyl alcohol-polyethylene glycol grafted copolymer; the capsule material and the content of the capsule material are optimized, the encapsulation efficiency and the yield are remarkably improved, and the finally prepared preparation is relatively low in content of related substances, can be stored and applied for a long time and has a very good development value.

The application provides a fast-acting flunixin meglumine injection and a preparation method thereof, and belongs to the technical field of veterinary medicine, and contains the following components: flunixin meglumine 5-10 (w / v) %, alpha-pyrrolidone 10-30 (w / v) %, hydrophilic solvent 0.5-1 (w / v) %, antioxidant 0.1-0.3 (w / v) % and the balance of water for injection. The application takes flunixin meglumine as the main drug, matches alpha-pyrrolidone as a solvent and a targeting guide distribution component, uses a hydrophilic solvent to assist dissolution and promote absorption, and uses an antioxidant to inhibit the oxidative degradation of the main drug, so that the dissolution and absorption rate of the main drug and the target tissue distribution efficiency can be effectively improved, the storage stability can be ensured, the bacterial endotoxin and the injection site redness rate meet the requirements, the acute inflammation and pain of livestock and poultry can be quickly and efficiently relieved, and the demand for instant intervention in large-scale breeding can be met.

The application belongs to the technical field of medicine, and particularly discloses a small-molecule indometacin hydrogel and a preparation method thereof. The small-molecule hydrogel is obtained by mixing indometacin and a small-molecule ligand, adding a small amount of deionized water, and oscillating. The small-molecule hydrogel has the advantages of solubility and permeability, with the small-molecule ligand as a matrix. The formed small-molecule hydrogel can significantly improve the solubility and dissolution / release rate of indometacin. Compared with indometacin crystals, the water solubility of the two small-molecule hydrogels of indometacin-meglumine and arginine is increased by 506 times and 479 times, respectively, and the cumulative release rate at 2h is increased by 2.67 times and 3.05 times, respectively. Meanwhile, the small-molecule hydrogel significantly promotes the membrane permeability of indometacin, enhances the development potential of indometacin in oral and transdermal applications, and provides a new preparation idea for solving the solubility and permeability defects of non-steroidal anti-inflammatory drugs and other poorly soluble drugs.

The present invention provides a gadoteric acid meglumine injection and a preparation method thereof, relating to the technical field of contrast agents. The present invention involves a first mixing of DOTA with a first portion of water to obtain a first solution; a second mixing of a second portion of water and a cosolvent with the first solution; and a pH adjuster to adjust the pH of the system to obtain a second solution; the pH adjuster comprises meglumine and an organic weak acid, the organic weak acid being at least one of citric acid, tartaric acid, and lactic acid; and a third mixing of the second solution, gadoteric acid meglumine, and the remaining water to obtain gadoteric acid meglumine injection; the gadoteric acid meglumine is injection-grade gadoteric acid meglumine. The method provided by the present invention is used to prepare gadoteric acid meglumine injection, which does not exhibit gadolinium ion leakage at low DOTA concentrations and has a low impurity content.

The invention discloses a pharmaceutical composition containing linagliptin and metformin hydrochloride and a preparation method thereof.According to the composition, a small amount of meglumine (0.01%-1.0% w / w) is added, a linagliptin mixture and a metformin hydrochloride mixture are separately granulated, the growth of an impurity A, an impurity B and total impurities in an obtained linagliptin and metformin hydrochloride tablet is slow, the content of impurities in the linagliptin and metformin hydrochloride tablet is low, and the content of impurities in the linagliptin and metformin hydrochloride tablet is high. The stability of the composition is obviously improved, and the dissolution effect is not influenced. According to the preparation method of the composition, auxiliary materials in the preparation process are easy to obtain, the price is low, and the composition is suitable for commercial production.